U.S. License Holder:
Biovitrum AB
Date of License:
December-15-2004
Last Update:
Oct-23-2024
FDA-Approved Indications
KEPIVANCE (palifermin) is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in WHO Grade 3 or greater mucositis in the majority of patients.